Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Clinical effectiveness of the angiotensin converting enzyme inhibitor, Ramipril, in patients with intermittent claudication: Randomised, double-blind, placebo-controlled trial

Shahin, Yousef 2015. Clinical effectiveness of the angiotensin converting enzyme inhibitor, Ramipril, in patients with intermittent claudication: Randomised, double-blind, placebo-controlled trial. MD Thesis, Cardiff University.
Item availability restricted.

[thumbnail of 2015SHAHINYMD.pdf]
Preview
PDF - Accepted Post-Print Version
Download (5MB) | Preview
[thumbnail of 2015SHAHINY_THESIS PUBLICATION FORM.pdf] PDF - Supplemental Material
Restricted to Repository staff only

Download (201kB)

Abstract

Background The HOPE trial showed that ramipril reduced cardiovascular morbidity and mortality in patients with peripheral arterial disease (PAD). However, evidence regarding the effect of angiotensin converting enzyme (ACE) inhibitors on walking distance, ankle brachial pressure index (ABPI), arterial stiffness and quality of life (QoL) in this group of patients is limited. Objective The aim of this study is to investigate ACE inhibitors effect on clinical parameters of PAD, arterial stiffness and QoL in patients with intermittent claudication (IC). Methods 33 patients (25 males, mean age: 65+/-7.8) with IC (Fontaine stage II or higher) were randomised to receive ramipril (5 mg once daily for 2 weeks increased to 10 mg once daily for 22 weeks, n=14) or placebo (n=19) for 24 weeks in a double-blind study. Walking distance was assessed using a standard laboratory treadmill test (2.5 km/hr at 10% incline). ABPI was assessed pre (r-ABPI) and post-exercise (t-ABPI). Arterial stiffness indices were measuredusing the SphygmoCor device. Results After 24 weeks, ramipril improved maximum treadmill walking distance; adjusted mean change difference (95% confidence interval); by 130.5 (61.8 to 199.2) m longer than placebo (P=0.001), improved treadmill intermittent claudication distance by 121.9 (55.9 to 187.8) m longer than placebo (P=0.001) and improved patient reported walking distance by 159 (5.5 to 313) m compared to placebo (P=0.040). Ramipril reduced carotid femoral pulse wave velocity (a measure of arterial stiffness) by -1.47 (-2.4 to -0.57) m/s compared to placebo (P=0.002). However, r-ABPI and t-ABPI minimally changed in both groups (Ramipril 0.02 (-0.08 to 0.11) vs. placebo 0.03 (-0.05 to 0.10, P=0.830) and (Ramipril 0.04 (-0.04 to 0.12) vs. placebo 0.02 (-0.04 to 0.09), P=0.720), respectively. Ramipril had a slight insignificant effect on QoL physical domains compared to placebo. Conclusion Ramipril improves walking distance in patients with IC; however, this improvement is not related to improvement in ABPI but might be due to ramipril ability to reduce arterial stiffness. ACE inhibitors effect on QoL needs to be validated in a larger randomised controlled trial.

Item Type: Thesis (MD)
Status: Unpublished
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Date of First Compliant Deposit: 30 March 2016
Last Modified: 01 Mar 2022 14:27
URI: https://orca.cardiff.ac.uk/id/eprint/77988

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics